PDZK1在子宫内膜癌中的表达及临床意义

Expression of PDZK1 in endometrial carcinoma and its clinical significance

目的检测PDZK1基因在子宫内膜癌中的表达并探讨其临床病理学意义。方法应用实时荧光定量PCR、蛋白免疫印迹和免疫组化实验方法,检测重庆医科大学附属第一医院2012年1月至2017年6月收治的53例子宫内膜癌患者术后组织标本及32例正常子宫内膜标本中PDZK1基因mRNA和蛋白表达。分别应用χ2检验、Kaplan-Meier和对数秩检验对PDZK1表达及与临床病理因素、无病生存(disease-free survival,DFS)和总体生存时间(overall survival,OS)进行关联分析。结果PDZK1 mRNA和蛋白在子宫内膜癌组织中的表达高于正常子宫内膜组织(2. 415±0. 663 vs 0. 986±0. 322,P <0. 05; 1. 412±0. 280 vs 0. 350±0. 210,P <0. 05);较高的PDZK1表达与肿瘤低分化(P <0. 01)、FIGO晚期(P <0. 05)和淋巴结转移(P <0. 05)呈正相关而与年龄、是否绝经无关(P> 0. 05),且高PDZK1表达患者具有较短的DFS(P <0. 05)和OS(P <0. 05)。结论 PDZK1在子宫内膜癌中高表达,与肿瘤低分化、FIGO晚期、淋巴转移和不良预后相关。

Objective To investigate the expression of PDZK1 in endometrial carcinoma and explore its correlation with the clinicopathological features of the patients. Methods RT-PCR,Western blotting and immunohistochemistry were used to detect the expression of PDZK1 at mRNA and protein levels in 53 specimens of endometrial carcinoma tissues and 32 normal endometrial specimens obtained in the First Affiliated Hospital from January 2012 to June 2017. Chi-square test,Kaplan-Meier analysis,and log-rank test were used to analyze the correlation of PDZK1 expression with the clinicopathological factors,disease-free survival( DFS),and overall survival( OS) time of the patients. Results The endometrial carcinoma tissues showed significantly higher expressions of PDZK1 than normal endometrial tissues at both the mRNA( 2. 415 ±0. 663 vs 0. 986 ± 0. 322,P < 0. 05) and protein levels( 1. 412 ± 0. 280 vs 0. 350 ± 0. 210,P < 0. 05). A high PDZK1 expression was positively correlated with a lower grade tumor differentiation( P < 0. 01),an advanced FIGO stage( P < 0. 05) and lymph node metastasis( P < 0. 05),but was not related to age or the menopausal status of the patients( P > 0. 05). The patients with high PDZK1 expression had significantly shorter DFS( P < 0. 05) and OS time( P < 0. 05). Conclusion PDZK1 is highly expressed in endometrial carcinoma and associated with a poor tumor differentiation,an advanced FIGO stage,lymphatic metastasis and a poor prognosis of the patients,suggesting its value as a new biomarker as well as a therapeutic target of endometrial carcinoma.